FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Bionpharma Inc.)

View source ↗

Summary

FDA approved a supplemental application for ibandronate sodium submitted by Bionpharma Inc. under ANDA078998.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• IBANDRONATE SODIUM (ibandronate sodium)

Snippet

SUPPL AP for IBANDRONATE SODIUM (IBANDRONATE SODIUM)